ArticleEpidemiology and infection2025
Penetration of SARS-CoV-2 Alpha, Delta, and Omicron variants in the United States.
Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Alpha, Delta, and Omicron variants of the SARS-CoV-2 virus have been deemed as variants of concern (VOCs) by the WHO due to their increased transmissibility, severity of illness, and resilience against treatments. Geographically tracking the spread of these variants can help us implement effective control measures. RNA from 8,154 SARS-CoV-2 positive nasal swab samples from a Central Texas hospital collected between March 2020 and April 2023 were sequenced in Temple, TX. Global and U.S. sequencing metadata was obtained from the GISAID database on 3 April 2023. Using sequencing metadata, the growth rate of Alpha, Delta, and the first subvariant of Omicron (BA.1) were obtained as 0.27, 0.3, and 1.08 each. The average time in days to penetrate the US for Alpha, Delta, and Omicron were 269.2, 326.2, and 27.3 days, respectively. Viral sequencing data can be a useful tool to examine the spread of viruses. Each emerging SARS-CoV-2 variant penetrated cities more rapidly as the pandemic progressed. With a high logarithmic growth rate, the Omicron variant penetrated the US more rapidly as the pandemic progressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.